Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + albumin-bound paclitaxel + cisplatin + carboplatin
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy consists of QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4), albumin-bound paclitaxel (nab-paclitaxel), and platinum-based chemotherapy (cisplatin or carboplatin). It is being investigated as a neoadjuvant treatment for patients with locally advanced cervical cancer (FIGO 2018 stage IB3-IIA2). QL1706, developed by Qilu Pharmaceutical, simultaneously blocks the PD-1 and CTLA-4 pathways to enhance the immune response against tumor cells, while the chemotherapy components provide direct cytotoxic effects. The regimen aims to down-stage tumors before radical surgery.
- Other names
- iparomlimab + nab-paclitaxel + cisplatin + carboplatintuvonralimab + nab-paclitaxel + cisplatin + carboplatinQL1706 + nab-paclitaxel + cisplatin + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA
Beyond the preview
Go deeper on QL1706 + albumin-bound paclitaxel + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + albumin-bound paclitaxel + cisplatin + carboplatin.